Multiplex protein signature for the detection of bladder cancer in voided urine samples

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2257-2262

  Rosser, Charles J ^a   Ross, Shanti ^a   Chang, Myron ^b   Dai, Yunfeng ^b   Mengual, Lourdes ^c   Zhang, Ge ^a   Kim, Jeongsoon ^a   Urquidi, Virginia ^a   Alcaraz, Antonio ^c   Goodison, Steve ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biological markers; Diagnosis; Molecular biology; Urinary bladder neoplasms; Urine

Indexed keywords

ANGIOGENIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; GELATINASE B; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN 2; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYTOGENETIC TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMAN; KIDNEY CONCENTRATING CAPACITY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINARY TRACT INFECTION; URINE CYTOLOGY; UROLITHIASIS;

EID: 84888637997     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.011     Document Type: Article

References (29)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10.
2. Aben KK and Kiemeney LA: Epidemiology of bladder cancer. Eur Urol 1999;36:660.
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680.
4. Herr HW: Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60.
5. Tetu B: Diagnosis of urothelial carcinoma from urine. Mod Pathol, suppl., 2009;22:S53.
6. Van Rhijn BW, Van Der Poel HG and Van Der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736.
7. Lokeshwar VB, Habuchi T, Grossman HB et al: Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, suppl., 2005;66:35.
8. Urquidi V, Goodison S, Cai Y et al: A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2149.
9. Yang N, Feng S, Shedden K et al: Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011;17:3349.
10. Goodison S, Chang M, Dai Y et al: A multianalyte assay for the non-invasive detection of bladder cancer. PLoS One 2012;7:e47469.
11. Bossuyt PM, Reitsma JB, Bruns DE et al: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 2004;21:4.
12. Reid CN, Stevenson M, Abogunrin F et al: Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat. PLoS One 2012;7:e53354.
13. McQuarrie A D R and Tsai CL: Regression and Time Series Model Selection. Singapore: World Scientific Publishing 1998.
14. Austin PC and Tu JV: Bootstrap methods for developing predictive models. Am Stat 2004;58:131.
15. Edgar R, Domrachev M and Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207.
16. Fluss R, Faraggi D and Reiser B: Estimation of the Youden Index and its associated cutoff point. Biom J 2005;47:458.
17. Grossman HB, Messing E, Soloway M et al: Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810.
18. Heicappell R, Wettig IC, Schostak M et al: Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999;35:81.
19. Nguyen B, Cusumano PG, Deck K et al: Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 2012;19:3257.
20. Malo TL, Lipkus I, Wilson T et al: Treatment choices based on OncotypeDx in the breast oncology care setting. J Cancer Epidemiol 2012;2012:941495.
21. Bartoletti R, Cai T, Dal Canto M et al: Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 2006;175:2032.
22. Sheryka E, Wheeler MA, Hausladen DA et al: Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003;62:162.
23. Sagnak L, Ersoy H, Ozok U et al: Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guerin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer 2009;7:E16.
24. Hudson MA and McReynolds LM: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 1997;89:709.
25. Span PN, Witjes JA, Grebenchtchikov N et al: Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int 2008;102:177.
26. Offersen BV, Knap MM, Horsman MR et al: Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol 2010;49:1283.
27. Eissa S, Ali-Labib R, Swellam M et al: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 2007;52:1388.
28. Newman DJ, Pugia MJ, Lott JA et al: Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin Chim Acta 2000;294:139.
29. Sarosdy MF, Schellhammer P, Bokinsky G et al: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950.